Adam Koppel, M.D., Ph.D.

Managing Director, Bain Capital

Dr. Adam M. Koppel is Managing Director of Bain Capital Life Sciences. He initially joined Bain Capital Public Equity in 2003, where he worked as a leader within the healthcare sector until 2014. From 2014 to 2016, Adam was EVP of Corporate Development and Chief Strategy Officer at Biogen.

Adam sits on the Board of Directors of Solid Biosciences, Dicerna Pharmaceuticals, Aptinyx, and Foghorn Therapeutics. Adam also sits on the Newton-Wellesley Hospital Board of Trustees, the Partners Healthcare Innovation Advisory Board, and the Society for Neuroscience Investment Committee. He serves on the Board of Trustees of the Boston Museum of Science. In addition, He previously sat on the Board of Temple Beth Elohim in Wellesley, Massachusetts, from 2014 to 2017.

Adam received an M.D. and Ph.D. in neuroscience from the University of Pennsylvania School of Medicine. He also received an MBA from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Harvard University with bachelor’s degrees in history and science.